DC-CIK免疫治疗晚期胰腺癌的临床疗效分析

Clinical efficacy of DC-CIK immunotherapy in treatment of advanced pancreatic adenocarcinoma

目的:分析和比较DC-CIK治疗联合姑息或化疗治疗晚期胰腺癌的有效性及安全性。方法:回顾性分析2012年2月至2016年12月就诊于山西大医院肿瘤内科进行治疗的晚期胰腺癌患者50例,根据治疗方式分为姑息治疗组、姑息治疗+DC-CIK治疗组、化疗组和化疗+DC-CIK治疗组,评估治疗前后患者细胞免疫功能、生活质量及生存期等,并观察DC-CIK细胞治疗的有效性及安全性。结果:DC-CIK联合组治疗后患者CD8+、NKT细胞较治疗前细胞百分比有明显提高,与对照组相比CD3+、CD8+、NK、NKT细胞百分比均有提高(P<0.05);患者生活质量均有不同程度提高,m PFS及m OS无明显延长(P>0.05)。结论:与单纯姑息治疗和化疗相比,联合DC-CIK免疫治疗可以有效地提高晚期胰腺癌患者细胞免疫功能和改善患者生活质量,但对患者总生存期无明显延长。

Objective： To analyze and compare the clinical efficacy and safety of dendritic cell cytokine-induced killer cells（DCCIK） combined with palliative therapy or chemotherapy in the treatment of advanced pancreatic carcinoma. Methods： A retrospective study was carried on 50 patients with advanced pancreatic carcinoma who were hospitalized in department of oncology of Shanxi Dayi Hospital during September 2012 to February 2016. The patients were divided into four groups according to the therapy they received（palliative treatment group, palliative ＋ DC-CIK treatment group, chemotherapy group and chemotherapy ＋ DC-CIK treatment group）;the immunological function, quality of life and survival time of patients were analyzed; and the efficacy and safety of DC-CIK cell therapy was also evaluated. Results： The percentages of CD8＋T cells and NKT cells in DC-CIK combined therapy groups were significantly improved compared with that of pre-treatment, and the percentages of CD3＋, CD8＋, NK, NKT cells were increased compared with control groups（P〈0.05）. The quality of life of patients was significantly improved（P〈0.05）, while median PFS and median OS were improved but without statistical significance（P〉0.05）. Conclusion： Compared with palliative therapy and chemotherapy alone, combined DC-CIK immunotherapy can effectively improve the cellular immunity function and quality of life in patients with advanced pancreatic cancer. However, there was no significant extension in overall survival.